 Treatment fulminant viral hepatic failure prostaglandin preliminary report effect prostaglandins PG patients fulminant subfulminant viral hepatitis Seventeen patients FHF secondary hepatitis non-A non-B NANB hepatitis patients stage III IV hepatic encephalopathy HE presentation mean AST units/liter bilirubin mumol/liter PT PTT sec coagulation factors VII Twelve patients decrease AST units/liter decrease prothrombin time sec sec PTT sec sec increase factor factor VII responders NANB hepatitis discontinuation therapy recurrence HE AST PT improvement retreatment weeks intravenous therapy oral patients remission months cessation therapy additional patients remission months relapses patients hepatitis virus HAV hepatitis virus HBV infection Liver biopsies patients normal results efficacy PGE FHF Further investigation